Skip to main content

CBT for Mood
vs
SSRIs for Hot Flashes

A side-by-side comparison of two menopause relief methods — efficacy, cost, how they work, and who shouldn't use them.

Side-by-side comparison

Method
CBT for Mood

CBT for Mood

A structured talk therapy program to manage anxiety, depression, and emotional changes during menopause.

SSRIs for Hot Flashes

SSRIs for Hot Flashes

A low-dose SSRI (paroxetine 7.5 mg) approved by the FDA for moderate-to-severe hot flashes.

EfficacyRecommended see details

Recommended by the Menopause Society for symptom relief.

Recommended see details

Recommended by the Menopause Society for symptom relief.

Cost$0–$200 /per unit

Insurance: Usually

$0–$200 /monthly

Insurance: Usually

Duration6-8 weekly sessionsDaily pill (ongoing)
ReversibilityReversibleReversible
STI ProtectionNoNo
How it works

Cognitive Behavioral Therapy (CBT) for mood helps women identify and modify unhelpful thought patterns and behaviors that contribute to anxiety, depression, and emotional distress during the menopause transition. It combines cognitive restructuring (challenging negative automatic thoughts), behavioral activation (re-engaging in rewarding activities), stress management skills, and psychoeducation about menopause. Unlike medication, it does not alter hormones or neurotransmitters directly.

Low-dose paroxetine affects serotonin and other neurotransmitters involved in temperature regulation, which can reduce hot flash frequency and severity.

PrescriptionOTC Therapist-delivered (no Rx)Required Prescription required
Available ProductsNo branded products yet1 product
Side effects
  • Temporary increase in emotional distress when discussing difficult feelings (usually transient)
  • No physical side effects
  • Nausea
  • Headache
  • Fatigue or malaise
Who shouldn't use this
  • Active suicidality (requires crisis-level psychiatric care, not outpatient CBT alone)
  • Severe depression requiring immediate medication (CBT may be used alongside medication but not as sole treatment)
  • Active mania or psychosis
  • Current or recent MAOI use (within 14 days)
  • Concomitant thioridazine or pimozide
  • Pregnancy
  • Hypersensitivity to paroxetine or any ingredient